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Lysosomal storage diseases arise because of genetic
mutations that result in nonfunctioning or dysfunctional
lysosomal enzymes responsible for breaking down mol-
ecules such as glycosaminoglycans or glycogen. Many of
these storage diseases, such as the mucopolysaccharido-
sis (MPS) disorders and Pompe disease, can now be
treated with infusion therapies to replace the dysfunc-
tional protein with active enzyme. Although these
therapies are effective, in at least one condition,
infantile-onset Pompe disease, antibodies that develop
against the drug signiﬁcantly reduce its efﬁcacy. How-
ever, this inﬂuence on efﬁcacy does not appear to
manifest across all enzyme replacement therapies. An
example is MPS IVA, or Morquio A syndrome, in which
the glycosaminoglycans keratan sulfate and chondroitin-
6-sulfate accumulate in tissues as a result of N-acetylga-
lactosamine-6-sulfatase deﬁciency. The current approved
treatment for MPS IVA is elosulfase alfa, a recombinant
human enzyme replacement therapy. Although all pa-
tients receiving elosulfase alfa treatment develop anti-
drug antibodies and most develop neutralizing
antibodies, clinical data to date show no effect on drug
efﬁcacy or safety. Overall, the relevance of antidrug
antibodies speciﬁc to enzyme replacement therapies for
the lysosomal storage diseases remains a mixed picture
that will require time and continued clinical follow-up to
resolve for each speciﬁc condition and treatment. (Clin
Ther. 2015;37:2130–2134) & 2015 The Authors. Pub-
lished by Elsevier HS Journals, Inc.
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Lysosomal storage diseases are characterized by fail-
ure of function of 1 or more lysosomal enzymes.1,22130The result of the lost function is accumulation in
tissues of the enzyme’s target molecule, and these
conditions present with a broad spectrum of manifes-
tations depending on the severity of the mutation,
speciﬁc target molecule, and tissues most affected.
Most of these diseases are inherited in an autosomal
recessive manner with some exceptions, such as Fabry
disease (X linked)3 and one of the mucopolysac-
charidosis (MPS) disorders, MPS II (Hunter
syndrome; OMIM 309900; also X linked). Eleven
lysosomal enzyme deﬁciencies are classiﬁed as MPS
disorders,2 including MPS IVA (Morquio A syndr-
ome; OMIM 253000).
In MPS IVA, a deﬁciency in the enzyme N-acetyl-
galactosamine-6-sulfatase (GALNS) leads to lysoso-
mal accumulation of its target molecules, the
glycosaminoglycans keratan sulfate and chondroitin-
6-sulfate.4,5 This accumulation affects a variety of
organ systems, including bone, respiratory, cardiovas-
cular, visual, auditory, and hepatic tissues.6
Individuals with MPS IVA do not usually show
signs of the condition at birth but eventually present
with progressive disease. They typically have severe
skeletal dysplasia characterized by dwarﬁsm, hip and
spine abnormalities, and joint instability and hyper-
mobility as a result of the lax ligaments that distin-
guish this condition from other mucopolysaccharide
diseases. Progression of skeletal disease can lead to
neurological impairments from compression myelop-
athy, but the central nervous system is generally
considered to be unaffected, in contrast to all other
MPS disorders except for MPS VI.6,7Volume 37 Number 9
P. HarmatzIn the absence of treatment, death usually occurs in
the second or third decade for MPS IVA patients who
experience rapid disease progression, which is char-
acterized by rapidly worsening dysostosis multiplex,
limited growth, and high urinary keratan sulfate (uKS)
values.8 In patients with a slower disease progression,
the various system manifestations, including skeletal,
develop less rapidly but eventually do arise, and life
expectancy for this group is usually no greater than
the sixth decade.9 MPS IVA, which follows an
autosomal recessive pattern of inheritance, occurs in
1 in 76,000 to 640,000 live births globally.10
ENZYME REPLACEMENT THERAPY WITH
ELOSULFASE ALFA
Efficacy and Safety
The current treatment for MPS IVA is infusion with
replacement enzyme in the form of recombinant human
GALNS (elosulfase alfa*). This drug, which received
approval from the US Food and Drug Administration
in February 2014, is administered once weekly (2 mg/kg
infusion; VIMIZIM prescribing information11). Clinical
trials have demonstrated the effectiveness of weekly elosu-
lfase alfa infusion in increasing endurance, as measured
by the 6-minute walk test (6MWT), the primary efﬁcacy
measure in the Phase III trial (MOR-004). The Phase III
randomized, placebo-controlled trial also demonstrated
the effect of weekly elosulfase alfa in reducing uKS
values,10,12 one of the secondary outcomes; higher levels
of uKS have been associated with more severe impair-
ment.9 The 3-minute stair climb, the trial’s other secon-
dary outcome, remained unaffected by treatment.
Based on ﬁndings from the Phase III trial, elosulfase
alfa has an acceptable safety proﬁle, with the most
frequent adverse events being rated as mild to moderate
infusion-associated reactions.12 In MOR-004 (the piv-
otal Phase III study), hypersensitivity reactions occurred
in about one ﬁfth of patients and were usually mild to
moderate,12 but only 10% of patients in this trial tested
positive for immunoglobulin E.13
Earlier multicenter, open-label dose-escalation tri-
als (MOR-002) showed similar improvements in the
6MWT, which were sustained during almost 3 years
of follow-up in the MOR-100 extension study.14 This
maintenance of endurance over a period of years is
clinically relevant for a patient population that,
without treatment, would experience decline.9,15*VIMIZIM, BioMarin Pharmaceutical Inc. (Novato, California).
September 2015Although these longer term ﬁndings are promising,
further analysis is needed to investigate the effect of
antidrug antibodies (ADAs) and neutralizing antibod-
ies on long-term treatment efﬁcacy and safety.16
Enzyme Replacement Therapy and
Immunogenicity
Describing the relationship between efﬁcacy and
antibodies is relevant in the context of enzyme replace-
ment because of the lessons learned from enzyme
replacement therapy (ERT) for infantile-onset Pompe
disease.17 Pompe disease is also a lysosomal storage
disorder, arising from a deﬁciency in acid-alpha
glucosidase, one of the enzymes responsible for break-
ing down glycogen. The result is a buildup of the
carbohydrate in the heart and skeletal muscles. The
disease occurs in 3 forms, including infantile onset,
which is characterized by relatively rapid progression
and usually death by the age of 2 years. The ERT for
this condition, alglucosidase alfa†, has proved effective
in extending ventilator-free survival in this patient
population, but a drug-speciﬁc antibody response has
been associated with a critical loss of efﬁcacy.18,19
The impact on efﬁcacy of the drug-speciﬁc antibody
response to alglucosidase alfa has speciﬁcally been
linked to the presence or absence of endogenous
immune-reactive material in the form of incomplete
or nonfunctional protein, known as cross-reactive
immunological material (CRIM).18 Among the
lysosomal storage diseases, CRIM status has been
noted as a determining factor of clinical outcome for a
subset of Pompe patients, those with infantile-onset
Pompe who are CRIM negative. CRIM-negative
patients with infantile-onset Pompe would be expected
to lack endogenous protein and are reported to be
more likely to develop high, lasting antibody titers and
have a worse clinical outcome compared with their
CRIM-positive counterparts.17,18,20 The hypothesis is
that the presence of even limited acid-alpha glucosi-
dase material from birth in CRIM-positive individuals
could prime the immune system to recognize the
infused alglucosidase alfa as “self” and not mount a
response; in the absence of these priming molecules,
the replacement enzyme triggers antibody production.
This interpretation has, however, been brought into
question by ﬁndings of high ADA titers in some CRIM-
positive patients21 and low19 or moderate22 titers in†Myozymes (Genzyme Corp., Boston, Massachusetts).
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11 children with infantile-onset Pompe,19 ADA titers
did not correlate with CRIM status. In addition, the 4
patients in that study who were CRIM negative died
before 4 years of age regardless of their antibody titers,
implicating some other factor related to CRIM status.
These authors suggest that an early start to therapy,
before 2 months of age, played a role in lower antibody
titers in their patient group. Another report described
an adult patient who was CRIM positive with a high
antibody titer and who experienced reduced algluc-
osidase alfa efﬁcacy.19 Current practice in Pompe
disease involves treatment with immunosuppressant
drugs to induce tolerance to the ERT in CRIM-
negative/antibody-positive patients.18,23
The type of mutation may be relevant to the
antibody story in some other lysosomal storage dis-
orders. In Fabry disease, for example, patients who
have nonsense mutations are more likely than those
with missense mutations to develop ADAs.24 In a
study of 36 MPS II (Hunter syndrome) patients
receiving idursulfase ERT, Barbier et al.25 found that
those with nonsense or frameshift mutations were
more likely to develop antibodies and show a re-
duced urinary glycosaminoglycan response compared
to their counterparts with missense mutations.
Nevertheless, antibody response was not related to
6MWT improvement, liver and spleen volume change,
or improvements in respiratory measures in their patients
receiving ERT. These authors suggested that the
antibodies do not shape clinical outcomes but might
serve as a marker of genotype (ie, nonsense/frameshift
versus missense). Antibodies to idursulfase developed in
about half of the MPS II patients in that study.
In contrast, for MPS IVA patients, any correlation
between genotype and antibody titer requires further
exploration, in part because genotype has not been
systematically determined in clinical trials and CRIM
status has not been addressed for this population.
However, unlike CRIM-negative patients with infa-
ntile-onset Pompe, most of whom have a nonsense or
frameshift mutation,26 many mutations identiﬁed in
MPS IVA involve missense-related changes, implying
the presence of some translated protein.27
Regarding early treatment as a possible way to evade
antibody-related complications, as has been suggested
for Pompe disease, early intervention with ERT is
beginning to be evaluated in MPS, with trials ongoing
for patients younger than 5 years of age. Results of2132studies in which a younger sibling begins ERT earlier
than an older sibling so far suggest improved outcomes
overall with earlier intervention.28,29
Elosulfase Alfa: Immunogenicity and
Pharmacokinetics/Pharmacodynamics and
Efficacy
The CRIM status ﬁndings in infantile-onset Pompe
disease, in which high or sustained antibody titers may
interfere with ERT efﬁcacy, has focused attention on
other ERTs and how antibody titers might inﬂuence
their effectiveness. Schweighardt et al.13 evaluated the
immunogenicity of elosulfase alfa in MPS IVA patients
participating in the MOR-004 Phase III trial. As they
describe in their paper, the outcome thus far differs
from that of infantile-onset Pompe disease and alglu-
cosidase alfa. Schweighardt et al. report that in the
Phase III trial, ADAs developed in all patients on
elosulfase alfa treatment, and antibodies developed in
most of them (96.6% on the every-other-week dosing
regimen and 98.3% on the weekly regimen) that could
interfere with in vitro binding to a target receptor (ie,
neutralizing antibodies). However, antibody titers did
not correlate with worsening 6MWT values or with
increased uKS. These authors also found no link
between antibody titers and hypersensitivity reactions,
and no pattern related to the presence of ADA
immunoglobulin E and hypersensitivity, anaphylaxis,
or treatment withdrawal. They note that monitoring
of immunogenicity and potential effects on safety and
efﬁcacy will continue in the postapproval setting.
A further analysis of the pharmacokinetics of the
drug during this Phase III trial30 indicated that total
antibody titers had no effect on drug clearance but
that NAb positivity was associated with a reduced
clearance rate and longer plasma half-life in patients
receiving a weekly dose. The implications of this effect
on clearance are unknown.
The reason for these very different outcomes with
ERT for different lysosomal storage disorders is un-
clear, but one possible explanation in the case of
elosulfase alfa arises from its short half-life, which
can be as little as 7 minutes at week 1 and peaks at only
35 minutes in plasma by week 22 of treatment, once
antibody is present. Schweighardt et al.13 hypothesize
that during infusion, elosulfase alfa may saturate
available antibody, leaving the remaining drug free to
bind the receptor and enter the cell via rapid clearance
through the target receptor. The presence of the drugVolume 37 Number 9
P. Harmatzand the antibody together in the plasma for only a
short amount of time additionally might reduce the
opportunity for immune complex formation.
Elosulfase alfa is not the only ERT that shows a
pattern of antibody positivity combined with continued
drug efﬁcacy. The lack of an association between efﬁcacy
and the presence of ADAs has also been reported for
ERT treatment for MPS I,31 MPS VI,32 and Fabry
disease.33 However, one study that included 30 men
being treated with one of the ERTs for Fabry disease for
up to 10 years suggested some reduced efﬁcacy in those
who were antibody positive.34 Deegan,35 in a review
from the same year, notes interpretation difﬁculties
related to the heterogeneity of both the disease
presentation in Fabry disease and therapeutic response.
Gaining a clear picture of the antibody–efﬁcacy
interaction is difﬁcult, even within a single condition.
FUTURE PERSPECTIVES
In the setting of lysosomal storage disorders, antibody
measures have been associated with a risk of reduced
ERT efﬁcacy in Pompe disease, a mixed set of outcomes
in Fabry disease, and no inﬂuence to date on the efﬁcacy
in MPS I or MPS VI. Joining the last group is elosulfase
alfa for MPS IVA. In all patients on elosulfase alfa
treatment, antibodies to the drug develop, but antibody
titers thus far show no correlation with efﬁcacy or safety.
With this latest contribution to the growing literature on
antibodies and end points in the ERT context, we see a
continued heterogeneity of antibody-related ﬁndings that
reﬂects the heterogeneity across these lysosomal storage
disorders and an overall difﬁculty in correlating antibody
levels and outcomes. As data continue to accumulate
over the long term, the underlying cause of this varia-
bility across disorders may become clearer. Meanwhile,
some limited evidence suggests that a focus on early
treatment—and thus early diagnosis—might be beneﬁcial
not only in terms of clinical outcomes but also for
preempting the antibody question altogether.
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